Unsubscribe

A message from Paradigm Press

Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.

---

Dear Reader,
 
It’s official…
 
SpaceX is going public…
 
And they’re saying it could be anywhere from $800 billion…
 
To $1.5 TRILLION!
 
To date, the biggest IPO ever was Saudi Aramco… at a mere $25.6 billion.
 
That means…

SpaceX’s IPO could be 58X BIGGERthan the largest IPO in history.

 Wall Street insiders are salivating at this massive stock move.
 
But here’s the thing…
 
You do NOT have to be left out of this once-in-a-lifetime opportunity.
 
In fact, you can get action on this SpaceX IPO right now – before it goes public, in a regular brokerage account …
 
And you can get into this play for less than $100.
 
Click here for the full story.
 
It sounds nuts…
 
But this is your chance to beat Wall Street to the punch…
 
And get a piece of the action on the BIGGEST IPO in history…
 
Before the news even hits the market.
 
Do NOT miss this opportunity.
 
Click here to learn how to claim your stake NOW.
 
Best,
Matt Insley

Publisher, Paradigm Press

---

Special Report

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

By Nathan Reiff. Posted: 1/19/2026. 

What You Need to Know

• Three biotech names with promising clinical trial data and a history of revenue generation stand out from the broader field for 2026.
• Atai Beckley and Evommune have promising pipelines focused on mental health disorders and inflammatory disease treatments, respectively.
• CorMedix has proven success with its catheter lock products and is expanding beyond the hemodialysis space in compelling ways.

Last year, the biotechnology industryleaned heavily into artificial intelligence (AI), using machine learning to identify drug targets, optimize molecules and predict trial outcomes. Alongside the continued spread of technology within the drug-development space, companies focused on obesity, rare diseases and oncology posted notable commercial achievements.

Heading into 2026, the landscape could continue to reward investors willing to accept higher risk. Lower interest rates and improved funding conditions may drive more investment in biotechs, particularly those with clear paths to commercialization. Many of the standout biotech stocks to watch in 2026 have tangible catalysts that could drive growth.

Atai Beckley: Potential Treatment for Major Mental Health Disorders

Best $19 you’ll spend this year. (Ad)

A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his “One Ticker” approach works — and how readers can access the full service for a year at a steep discount.Watch the brief demo here

Atai Beckley (NASDAQ: ATAI) develops therapies for mental health disorders, including treatment-resistant depression (TRD) and substance use disorders. Shares of this small-cap stock rose roughly 175% over the past year, despite a pullback in the final weeks of 2025. Investor enthusiasm in recent quarters was driven in part by the combination of atai Life Sciences and Beckley Psytech and a redomiciliation to the United States.

Investors should watch Atai Beckley for updates on BPL-003, a nasal spray in development for TRD and alcohol use disorder that reported positive topline results in a Phase 2b trial last July and additional promising data in November. A Phase 3 trial is expected to begin in the second quarter of 2026. The company’s pipeline is sizable and also includes other TRD candidates as well as a potential treatment for social anxiety disorder.

ATAI’s clinical momentum and the market opportunity are significant, but the company must manage high R&D expenses and very modest revenue. For that reason, 2026 could be a make-or-break year. Investors willing to take a chance on a promising TRD treatment may reap substantial rewards, but risk remains elevated.

Hemodialysis Wins and Expansion Could Drive CorMedix in 2026

We previously highlighted CorMedix Inc. (NASDAQ: CRMD) for its leadership in the catheter-lock market, where its DefenCath has shown potential to reduce catheter-related infections and hospitalizations among dialysis patients. The company’s potential blockbuster, however, may be REZZAYO, a treatment for candidemia that is currently in a Phase 3 trial, with data expected next quarter.

CorMedix is also expanding beyond hemodialysis, including its recent acquisition of Melinta Therapeutics, which is known for fungal and bacterial infection treatments. Melinta’s portfolio contributed roughly $13 million in sales in September alone, and the acquisition could provide an additional revenue lift when CorMedix reports full-year results.

The firm’s strong third-quarter 2025 results, which showed notable top- and bottom-line gains, along with a healthy cash position, should help buffer the company as healthcare reimbursement pressures persist in the coming year. That strength is reflected in analysts’ views: the consensus price target for CRMD is $17.86, about 153% above current levels.

Evommune: New Entrant with Upside in Atopic Dermatitis

Focused on chronic inflammatory diseases, Evommune (NYSE: EVMN) is the newest biotech on this list. The company went public in November 2025, and shares have climbed nearly 14% in the first two months of trading. Because it is newly public, investors have less historical data to evaluate, but there are reasons to expect 2026 could be a breakout year.

In the third quarter of 2025—the only quarterly report Evommune has filed since its IPO—the company highlighted Phase 2 data readouts for EVO756 and EVO301, aimed at chronic inducible urticaria and certain forms of atopic dermatitis, respectively. Top-line results from both trials are expected in early 2026 and could serve as significant catalysts.

Evommune ended the third quarter with a modest but healthy cash balance of $76 million and has begun generating revenue through a licensing agreement in Japan. Still, R&D expenses are likely to remain high. Analysts are optimistic about EVMN’s prospects, projecting more than 84% potential upside.

Thank you for subscribing to StockReport.com, our daily newsletter that highlights a new stock each day.

This email communication is a sponsored message for Paradigm Press, a third-party advertiser of StockReport.com and MarketBeat. 

If you have questions about your account, don’t hesitate to contact us at contact@stockreport.com.

If you no longer wish to receive email from StockReport.com, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC dba StockReport.com. 
345 North Reid Place, Sixth Floor, Sioux Falls, SD 57103-7078. United States of America..